Introduction {#Sec1}
============

Genetic polymorphisms in homologous recombination repair (HRR) genes, which can lead to protein haploinsufficiency have been associated with cancer risk \[[@CR1]\]. The RAD51, XRCC2 and XRCC3 proteins are core components of DNA double strand breaks (DSBs) repair by HRR. *XRCC2* and *XRCC3* genes are structurally and functionally related to the *RAD51* gene \[[@CR2]\]. Cell deficient with any of these genes product are defective in homologous recombination and demonstrate genomic instability \[[@CR3]--[@CR6]\]. Hamster cell lines deficient in *XRCC2* and *XRCC3* genes had an elevated frequency of aneuploidy compared with wild-type cells and mutant cells transfected with an appropriate human gene \[[@CR7]\]. *XRCC2*- and *XRCC3*-deficient hamster cell lines show also a high frequency of multiple centrosomes and abnormal spindle formation \[[@CR4]\]. CHO cell lines defective in XRCC2 and XRCC3 had lower spontaneous frequency of sister chromatid exchange than wild type cells \[[@CR8]\]. The most frequent polymorphism in the *XRCC3* gene is a C\>T transition resulting in an amino acid substitution of Thr to Met at codon 241. Carriers of the Met allele had relatively high DNA adducts level in lymphocyte DNA, which could be the result of lower DNA repair capacity \[[@CR9], [@CR10]\]. Conflicting results have been published on the association with colon cancer \[[@CR9], [@CR11]--[@CR15]\]. XRCC3-241Thr genotype was associated with adverse progression-free survival of colorectal cancer patients in one study \[[@CR13]\]. This polymorphism was also associated with a better prognosis for colorectal cancer patients \[[@CR14]\].

A relatively rare polymorphism in the XRCC2 gene, a G\>A transition resulting on Arg to His substitution at codon 188, was not found to be related with colorectal cancer (CRC) risk in two studies \[[@CR15], [@CR16]\].

Recently, we have shown that the 135G\>C (c. −98 G\>C; rs 1801320; Genbank accession number NT 010194) polymorphism can modify the effect of polymorphisms of the *BRCA2* and *XRCC3* genes on breast cancer occurrence \[[@CR17]--[@CR19]\].

In the present work we checked a potential influence of this polymorphism on the Thr241Met (c. 722 C\>T; rs 861539, Genbank accession number NT 026437) polymorphism of the *XRCC3* gene and the Arg188His (c. 563 G\>A; rs3218536, Genbank accession number NT 007914) polymorphism of the *XRCC2* gene on the colorectal cancer occurrence and clinicopathological parameters in a Polish subpopulation.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Blood samples were obtained from 100 patients (36 men and 64 women, median age 65, quartiles: 57, 75 years) with CRC treated during the study periods (2000--2001 and 2006--2007) at The Medical University of Lodz, Department of Gastroenterology and Internal Diseases and Department of Surgical Oncology, N. Copernicus Hospital, Lodz, Poland. Incidental patients consist of 90% of studied population. All patients had histologically confirmed invasive adenocarcinoma of the colon (Supplementary Table S1). A hundred sex- and age (±1 year)-matched individuals hospitalized due to their complains related to the lower gastrointestinal tract were enrolled as controls. They were examined by colonoscopy and subsequent histology of biopsies with no sign of colorectal cancer. Particularly, all controls had no macroscopic lesions of the colon mucosa reveled in the colonoscopy. Despite this, biopsies were taken every 10 cm along the whole colon and rectum from apparently normal mucosa in order to exclude individuals with early stages of mucosal dysplasia from the control group. All patients as well as controls were Caucasian. They accepted to cooperate and signed the informed consent. The protocol of the study was reviewed and approved by the Ethic Committee of the Medical University of Lodz and the experiment was conducted with the understanding and the consent of the human subject.

Genotype determination {#Sec4}
----------------------

Genomic DNA was prepared using the guanidine-isothiocyanate method as described previously \[[@CR18]\]. The polymorphisms were genotyped with restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR). *RAD51* genotyping was analysed by amplification of a 157-bp region surrounding the 135th nucleotide. This region contains a single *Mva*I site that was abolished in the C135C variant. Wild type alleles were digested by *Mva*I (Fermentas, Vilnius, Lithuania) producing 86 and 71 bp length products. The C135C variant of *RAD51* was not digested by the enzyme, giving a single 157 bp PCR product. PCR was performed in a MT Research, INC thermal cycler with the following primers: 5′-TGGGAACTGCAACTCATCTGG-3′ and 5′-GCGCTCCTCTCTCCAGCAG-3′ at a final Mg^2+^ concentration of 1.5 mM and annealing temperature 53°C. After overnight digestion with the enzyme, the samples were separated onto a 8% polyacrylamide gel. The Thr241Met polymorphism of the *XRCC3* was determined using the following primers: sense, 5′-GCCTGGTGGTCATCGACTC-3′; antisense, 5′-ACAGGGCTCTGGAAGGCACTGCTCAGCTCACGCACC-3′. The 136 bp PCR product was digested overnight with 3U of the restriction enzyme *Nco*I. The homozygous Thr/Thr genotype produced 39 and 97 bp fragments, heterozygous genotype three fragments: 136, 97 and 39 bp and the homozygous Met/Met genotype produced one 136 bp fragment. Restriction fragments were analysed on 3% agarose gels stained with ethidium bromide.

The Arg188His polymorphism of the *XRCC2* was determined using the following primers: sense, 5′-TGTAGTCACCCATCTCTCTGC-3′; antisense, 5′- AGTTGCTGCCATGCCTTACA-3′. The 290 bp PCR product was digested overnight with 3U of the restriction enzyme *Hph*I. The homozygous His/His genotype produced 148 and 142 bp fragments, heterozygous genotype three fragments: 290, 148 and 142 bp and the homozygous Arg/Arg genotype produced one 290 bp fragment. Restriction fragments were analysed on 8% polyacrylamide gels stained with ethidium bromide. We identified the product of particular reaction by comparing them with standards. We have chosen representative pictures of gels. Examples of gels are given on Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Representative PCR-RELP analyses on 8% polyacrylamide gel containing ethidium bromide. PCR-RELP band sizes are indicated on the *right of panel*. **a** The 135G\>C polymorphism of the *RAD51* gene. *Lane M*, DNA marker 25 bp (Fermentas); *lanes 1, 3 and 6* the G/G homozygote; *lane 2* the C/C homozygote; *lanes 4 and 5* the G/C heterozygote. **b** The Arg188His polymorphism of the *XRCC2* gene. *Lane M*, DNA marker 100 bp (Fermentas); *lanes 1 and 2* the His/His homozygote; and *lanes 3, 4 and 6* the Arg/Arg homozygote; *lane 5* the Arg/His heterozygote. **c** The Thr241Met polymorphism of the *XRCC3* gene. *Lane M*, DNA marker 25 bp (Fermentas); *lanes 1--4* the Thr/Met hetrozygote; *lane 5* the Thr/Thr homozygote; *lane 6* the Met/Met homozygote

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using STATISTICA 8.0 package (Statsoft, Tulusa, USA). Distributions of genotypes and alleles between groups were tested using Fisher's exact test. A linkage between SNP, cancer and clinicopathological parameters was accessed by the unconditional logistic regression (quasi-Newton method). For each SNP, odds ratio (OR) (single stage odds ratio for Duke's and TNM staging) was estimated. Wild type alleles or additional homozygous variants were used as reference groups. The Peto method was used for estimating odds ratios in cases with no events in one or both groups. Moreover, ORs for colorectal cancer were estimated in association with combinations of each two genotypes, defined on the basis of three SNPs in the *XRCC3*, *XRCC2* and *RAD51* genes. OR for each combination was calculated with homozygous wild type variants combination as the reference. All tests were two tailed. In all tests *P* values of less than 0.05 were considered statistically significant.

Results and discussion {#Sec6}
======================

We categorized all DNA samples according to the polymorphic variants and cancer occurrence and further in the case of cancer patients---also according to clinicopathological parameters. Table [1](#Tab1){ref-type="table"} displays the distribution of genotypes of the 135G\>C, Thr241Met and Arg188His polymorphisms. Among the controls, all genotype distributions did not differ significantly (*P* \> 0.05) from those expected by the Hardy--Weinberg equilibrium. The frequencies of genotypes of the Arg188His and Thr241Met polymorphisms did not differ significantly between patients and controls. Using the logistic regression we did not find any association between these polymorphisms and colorectal cancer occurrence. Our results on the association between the Thr241Met polymorphism of the *XRCC3* gene and colorectal cancer are in agreement with recent meta-analysis performed on 3,183/3,926 cases/controls \[[@CR20]\]. In case of the 135G\>C polymorphism of *RAD51* gene we found statistically significant differences among cases and controls. Colorectal cancer patients had lower frequency of C/C genotype (*P* \< 0.0001, statistical power 100%). This protecting effect was indicated also by odds ratio analysis (OR = 0.06, 95% CI 0.02--0.22). The current results on the association of the 135G\>C polymorphism of the *RAD51* gene and colorectal cancer are in agreement with our preliminary work \[[@CR21]\]. In the current work we added polymorphisms in two different genes, which enabled us to study the role of gene--gene interaction in colorectal cancer. Moreover, the control group was more age-homogenous than that in the preliminary research, which allowed us to decrease potential variation in the efficacy of DNA repair related to age. Differences in effectivity of DNA repair processes resulting from naturally occurred polymorphisms can affect the cancer risk \[[@CR22]--[@CR25]\]. Polymorphic genes of DNA repair are in great part included to low penetrance genes, which means that single gene product most often slightly affects the disease occurrence risk, but accumulation of changed alleles can have essential significance for its development. The combined effect of investigated *XRCC2*, *XRCC3* and *RAD51* polymorphisms on colorectal cancer occurrence has not been investigated, yet. The design of the study enabled us to investigate several gene--gene interactions in the context of general relationship between a gene and its structural analogues. Moreover, we performed our study on an ethnically homogenous population, which may contribute to our knowledge on the variation of genotype-phenotype relationship dependence on the population.Table 1Distribution of genotypes and odds ratios (OR) of the Arg188His polymorphism of the *XRCC2* gene (rs3218536) and the Thr241Met polymorphism of the *XRCC3* gene (rs861539) and the 135G\>C polymorphism of the *RAD51* gene (rs1801320) in colorectal cancerGenotype or allelePatients number (*N* = 100)Controls number (*N* = 100)OR^a^ (95% CI)*P* value\*Arg188His*P* trend = 0.4448 Arg188Arg75841.00 *ref.* Arg188His18141.44 (0.67--3.13)0.4387 His188His723.92 (0.78--19.8)0.0934Thr241Met*P* trend = 0.5203 Thr241Thr36501.00 *ref.* Thr241Met55471.62 (0.91--2.93)0.3185 Met241Met933.40 (0.99--11.7)0.0600G135C*P* trend = **0.0002** G135G61361.00 *ref.* G135C36350.60 (0.33--1.12)0.1545 **C135C3290.06 (0.02--0.22)\<0.0001**^a^Adjusted by age and sex\* Fisher's exact test

The frequencies of combined genotypes of *XRCC2*, *XRCC3* and *RAD51* genes are displayed in Supplementary Table S2. We found statistically significant differences between distribution of combined genotypes for colorectal cancer patients and control groups. Odds ratio analysis for a combination of the Arg188His polymorphism of *XRCC2* with the 135G\>C polymorphism of *RAD51* indicates protecting role of the C/C homozygous genotype against colorectal cancer in a Polish population (OR = 0.03; 95% CI 0.00--0.26, *P* \< 0.0001; statistical power 99.9%). Additional results were obtained for the combination of the Thr241Met polymorphism of the *XRCC3* gene and 135G\>C polymorphism of *RAD51* gene (OR = 0.07; 95% CI 0.00--0.56, *P* = 0.0021; statistical power 95.8% for Thr241Thr and C135C genotype and OR = 0.13; 95% CI 0.03--0.61; statistical power 93.6% for Thr241Met and C135C genotype).

Combination of variant homozygous His188His genotype of *XRCC2* gene with wild type variants of both *XRCC3* and *RAD51* polymorphisms increased the risk of colorectal cancer occurrence (OR = 12.4; 95% CI 1.63--94.9, *P* = 0.0259; statistical power 38.7% and OR = 5.88; 95% CI 1.21--28.5, *P* = 0.0391; statistical power 70.1%, respectively). This effect was also found for variant genotype of the *XRCC3* polymorphism in combination with wild type homozygous genotype of the *XRCC2* polymorphism (OR = 5.70; 95% CI 1.10--29.5, *P* = 0.0391; statistical power 52.4%).

Next, we divided colorectal cancer patients into groups depending on Duke's and TNM staging status. We did not found any relation between any group and polymorphism in the single stage OR analysis (Table [2](#Tab2){ref-type="table"}). To our knowledge it is the first study linking clinical parameters of colorectal cancer with *XRCC2*, *XRCC3* and *RAD51* polymorphisms.Table 2Combined genotype distribution and odds ratios (OR) of the Arg188His polymorphism of the *XRCC2* gene (rs3218536) and the Thr241Met polymorphism of the *XRCC3* gene (rs861539) and the 135G\>C polymorphism of the *RAD51* gene (rs1801320) in colorectal cancer patients according to clinicopathological parametersPolymorphismTNM stageDuke's stageGenotype or AlleleI (*N* = 36)II (*N* = 26)III (*N* = 38)OR^a^ (95% CI)\
*P* valueA (*N* = 30)B (*N* = 35)C + D (*N* = 35)OR^a^ (95% CI)\
*P* valueArg188His Arg188Arg2919271.00 *ref.*2329231.00 *ref.* Arg188His4681.40 (0.76--2.60)4591.37 (0.75--2.50)*0.26820.3028* His188His3131.03 (0.42--2.55)3130.99 (0.86--1.17)*0.94910.9967*Thr241Met Thr241Thr137161.00 *ref.*1212121.00 *ref.* Thr241Met2015201.01 (0.64--1.59)1520201.49 (0.64--3.54)*0.98140.3514* Met241Met3420.82 (0.37--1.85)3331.00 (0.57--1.75)*0.63140.9991*135G\>C G135G1816271.00 *ref.*1722221.00 *ref.* G135C171090.59 (0.36--0.97)1310130.57 (0.11--2.90)*0.03370.4930* C135C1021.58 (0.37--6.69)0302.00 (0.38--10.54)*0.51680.4109*^a^Single stage odds ratio adjusted by age and sex

We performed our study on relatively small populations of both patients and controls and we do not consider our results as definitive. Instead, they may be an important indicator for a larger cohort study, leading to establishing some more solid evidence. At present, we are unable to give a straight interpretation of some of our results. For example the XRCC2 Met241Met genotype was not associated with the occurrence of colon cancer, but it was associated with both increased risk in combination with XRCC3 Arg188Arg genotype and a decreased risk in combination with the RAD51 C135C genotype. This was probably due to a complex interaction between these polymorphisms, underlined by the mechanism requiring further studies.

Double strand DNA breaks are the most dangerous DNA damage. They occurred directly in cells as the result of endogenous and exogenous processes or as a result of a conversion of single strand breaks \[[@CR26]\]. Unrepaired can result in amplification or loss of genetic material which can result in neoplastic transformation by activation of oncogenes, inactivation of suppressor genes or loss of heterosigosity. It can be result of decrease of HRR fidelity or switch of repair over less correct process of non homologous end joining (NHEJ). It is also possible that genomic instability resulted from defective repair of double strand DNA breaks is an effect of increase of the gene expression not its reduction. The localization of the 135G\>C polymorphism of the *RAD51* gene in 5'UTR region indicates, that this polymorphism can be related to mRNA stability and translation. The *RAD51* gene transcript occurred in two main isoforms. Isoform I is 104 nucleotide longer, than isoform II, which is result of alternative splicing. Lost fragment of isoform II conteins 77% of GC base pairs \[[@CR27]\]. This sequence favors dimensional structures that negatively regulate translation \[[@CR28], [@CR29]\]. It seems to be possible that isoform II has greater translation potential. The isoform II level is lower in cell lines with the C/C genotype of 135G\>C polymorphism, therefore this genotype can be related to lower level of RAD51 protein.

Our results led us to hypothesis that colorectal cancer occurrence may be in part result of underexpression of *RAD51* gene. The cells with C/C genotype have low level of RAD51 protein. In this event other proteins such as XRCC2 and XRCC3 act in HRR process. Variant genotypes of these proteins have decreased repair capacity thus patients with this genotypes do not repair double strand DNA breaks efficiently by HRR.

In present work we showed that the 135G\>C polymorphism of the *RAD51* can modify the colorectal cancer risk alone as well as with association with other polymorphisms: the Thr241Met in *XRCC3* gene and the Arg188His in *XRCC2* gene. We showed also that all investigated polymorphisms 135G\>C of *RAD51*, Arg188His and Thr241Met of *XRCC3* should be simultaneously taken into account as a part of polygenic cause of colorectal cancer occurrence.
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